Data from the Italian National Registry indicate that hypertension provides a protective effective against early cerebrovascular events after transcatheter aortic valve implantation (TAVI). The variable also shows a tendency to protect against late events
A study has indicated that percutaneous edge-to-edge mitral valve repair with the MitraClip (Abbott Vascular) can be performed safely and effectively, in experienced centres, in both patients with central degenerative mitral regurgitation and those with non-central degenerative mitral regurgitation
PLC Systems reports that the first patient has been treated in a study designed to evaluate the effectiveness of its RenalGuard therapy for preventing acute kidney injury in patients undergoing transcatheter aortic valve implantation.
Cardiological Solutions has announced that it has been granted two additional patents for its family of aortic embolic protection devices, which are designed to prevent stroke and other ischaemic complications. The new patents include its first issued patent for its Emboline Cap technology and a further patent for its broad embolic deflector intellectual property portfolio.
Six-month results from the first 60 patients in the REPRISE II study show that Boston Scientific’s transcatheter aortic valve implantation (TAVI) device (Lotus) is not associated with any new cases of valve-related adverse events between 30 days and six months. The data won Best Abstract 2013 at PCR London Valves (15–17 September, London, UK).
JenaValve Technology has announced it has received CE mark approval from European regulators for its transapical TAVI system for the treatment of aortic insufficiency.
Boston Scientific has completed enrolment in the EVOLVE II randomised, controlled clinical trial. The EVOLVE II trial is designed to further assess the safety and effectiveness of the Synergy coronary stent system.
El Camino Hospital (Mountain View, USA), in partnership with the Taft Center for Clinical Research and the Fogarty Clinical Research Institute, both a part of the Fogarty Institute for Innovation, announces that it has enrolled its second patient in a global clinical trial comparing the CoreValve System (Medtronic) with surgical aortic valve implantation in patients with severe aortic stenosis who are at intermediate risk for open-heart surgery.
CardioLogical Solutions reports successful completed in vivo validation of its transcatheter aortic valve implantation (TAVI) access-and-closure device (VasoStitch).
Corindus Vascular Robotics has announced launch of the PRECISION Registry, an on-going study that will collect data on the safety and effectiveness of the use of the CorPath robotic angioplasty system in percutaneous coronary intervention (PCI) procedures
The novel anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim) should not be used to reduce the risk of stroke in patients with mechanical heart valves, the RE-ALIGN study has concluded. Its results indicate that compared with warfarin, the drug was associated with increased thromboembolic events and bleeding complications in this patient population.
Keystone Heart has announced that it can now commercially market its cerebral protection device, Triguard, for use in transcatheter aortic valve implantation (TAVI) procedures as the device has been awarded the CE mark.
Direct Flow Medical has announced that the first patient in its US SALUS clinical trial, which is evaluating the company’s transcatheter aortic valve implantation (TAVI) device, has been enrolled. The non-randomised, multicentre, core lab-adjudicated, investigational device exemption (IDE) trial of 30 patients is being conducted at six US clinical sites.
Boston Scientific Corporation (BSX) is scheduled to participate at the annual EuroPCR Scientific Program May 21-24 in Paris.
Results from the BIOSOLVE-I study that were presented at the EuroPCR have demonstrated the excellent safety profile of the DREAMS drug-eluting absorbable metal scaffold. Michael Haude, Lukaskrankenhaus, Neuss, Germany, one of the study s investigators, presented the results.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos